Company Overview and News
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078
KUALA LUMPUR (Oct 1): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 2) may include: AppAsia Bhd, Bioalpha Holdings Bhd, Dataprep Holdings Bhd, E.A. Technique (M) Bhd, IHH Healthcare Bhd, Malaysia Airports Holdings Bhd, Mexter Technology Bhd, Prestariang Bhd, Sealink International Bhd, Taliworks Corp Bhd, Astro Malaysia Holdings Bhd and Telekom Malaysia Bhd.
6399 5014 5145 0075 2852 0179 4863 5225 8338 MYPRY MYTEF Q0F IHHHF
KUALA LUMPUR (Oct 1): Sealink International Bhd is selling a 1.94ha land in Miri to an indirect wholly-owned unit of Cahya Mata Sarawak Bhd for RM26.5 million.
2852 BSMAF 5145 1818
KUALA LUMPUR (Sept 27): Maybank Investment Bank Bhd is issuing 15 new European style cash-settled call warrants which will be listed tomorrow (Sept 28, 2018), with an issue size of 100 million each.
4634 2852 4863 5148 BRDBF 5263 MYTEF HIPEF 7277 5210 5199
KUALA LUMPUR: Cahya Mata Sarawak Bhd (CMSB) has appointed Tan Sri Abdul Rashid Abdul Manaf as its independent and non-executive group chairman effective Oct 1.
2852 8206 8664
In a statement yesterday, CMSB said Abdul Rashid(pic), who is also EcoWorld’s founder director would take over the responsibility from interim group chairman Datuk Seri Mahmud Abu Bekir Taib, who reverts to the post of CMSB deputy group chairman.
KUALA LUMPUR (Sept 26): Cahya Mata Sarawak Bhd (CMSB) has appointed Tan Sri Abdul Rashid Abdul Manaf as its independent and non-executive group chairman effective Oct 1.
2852 8206 8664
Cahya Mata Sarawak Bhd (Aug 30, RM3.43) Maintain buy with an unchanged target price of RM4.10: With 16 furnaces operating at full capacity, Om Materials (Sarawak) Sdn Bhd (OMS) has begun to look at Phase 2 for expansion. Cahya Mata Sarawak Bhd (CMS) also has reiterated that it is already looking at alternative sources of supply for its premix raw materials. Growth estimates for financial year 2018 (FY18) remain intact, supported by OMS, construction and road maintenance.
Cahya Mata Sarawak Bhd (Aug 27, RM3.50) Maintain buy with a higher target price (TP) of RM4.59: We believe the share price will continue to recover from heavy selldown after a stellar performance in first half ended June 30, 2018 (1HFY18).
KUALA LUMPUR: JF Apex Research expects Sapura Energy Bhd , Cahya Mata Sarawak Bhd (CMSB), Southern Steel Bhd , Dayang Enterprise Holdings Bhd and Axiata Group Bhd to be among the stocks to watch on Monday.
4634 2852 0146 5665 6888 5141 AXXTF 7155
KUALA LUMPUR (Aug 24): Based on corporate announcements and news flow today, companies that will be in focus on Monday (Aug 27) may include: Sapura Energy Bhd, PUC Bhd, Axiata Group Bhd, Cahya Mata Sarawak Bhd, Magnum Bhd, Southern Steel Bhd, Dayang Enterprise Holdings Bhd, SKP Resources Bhd, MMC Corp Bhd, MSM Malaysia Holdings Bhd, Pos Malaysia Bhd, Paramount Corp Bhd and Adventa Bhd.
4634 2852 5665 6888 IDEA 5141 ICLQY AXXTF 5202 532822 7155
KUALA LUMPUR (Aug 24): Sarawak State infrastructure facilitator Cahya Mata Sarawak Bhd (CMSB) saw its net profit for the second quarter ended June 30, 2018 (2QFY18) leap by 59.5% to RM91.63 million from RM57.43 million mainly attributed to the increase in share of results of its associates.
2852 BSMAF 9466 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...